Ultimovacs ASA Statistics
Total Valuation
Ultimovacs ASA has a market cap or net worth of NOK 94.27 million. The enterprise value is -73.12 million.
Market Cap | 94.27M |
Enterprise Value | -73.12M |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024.
Earnings Date | Nov 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Ultimovacs ASA has 34.41 million shares outstanding. The number of shares has increased by 0.20% in one year.
Shares Outstanding | 34.41M |
Shares Change (YoY) | +0.20% |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 1.27% |
Owned by Institutions (%) | 17.78% |
Float | 23.60M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 0.43 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 0.41 |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | 0.41 |
Financial Position
The company has a current ratio of 7.84, with a Debt / Equity ratio of 1.38.
Current Ratio | 7.84 |
Quick Ratio | 7.80 |
Debt / Equity | 1.38 |
Debt / EBITDA | n/a |
Debt / FCF | -0.02 |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -59.69% and return on invested capital (ROIC) is -38.70%.
Return on Equity (ROE) | -59.69% |
Return on Assets (ROA) | -34.12% |
Return on Capital (ROIC) | -38.70% |
Revenue Per Employee | n/a |
Profits Per Employee | -7.79M |
Employee Count | 27 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -96.19% in the last 52 weeks. The beta is 1.09, so Ultimovacs ASA's price volatility has been similar to the market average.
Beta (5Y) | 1.09 |
52-Week Price Change | -96.19% |
50-Day Moving Average | 6.15 |
200-Day Moving Average | 55.22 |
Relative Strength Index (RSI) | 22.44 |
Average Volume (20 Days) | 629,452 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -188.30M |
Pretax Income | -179.27M |
Net Income | -179.27M |
EBITDA | -187.38M |
EBIT | -188.30M |
Earnings Per Share (EPS) | -5.21 |
Balance Sheet
The company has 170.40 million in cash and 3.01 million in debt, giving a net cash position of 167.39 million or 4.87 per share.
Cash & Cash Equivalents | 170.40M |
Total Debt | 3.01M |
Net Cash | 167.39M |
Net Cash Per Share | 4.87 |
Equity (Book Value) | 217.46M |
Book Value Per Share | 6.32 |
Working Capital | 155.40M |
Cash Flow
In the last 12 months, operating cash flow was -179.82 million and capital expenditures -17,000, giving a free cash flow of -179.83 million.
Operating Cash Flow | -179.82M |
Capital Expenditures | -17,000 |
Free Cash Flow | -179.83M |
FCF Per Share | -5.23 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Ultimovacs ASA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.20% |
Shareholder Yield | -0.20% |
Earnings Yield | -190.18% |
FCF Yield | -190.76% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |